Physiomics PLC
LSE:PYC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (0.5), the stock would be worth GBX-0.08 (115% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -3.2 | GBX0.5 |
0%
|
| Industry Average | 0.5 | GBX-0.08 |
-115%
|
| Country Average | 0.2 | GBX-0.03 |
-106%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Physiomics PLC
LSE:PYC
|
2.3m GBP | -3.2 | -3.1 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 2 167.8 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
178B USD | 12.3 | 25.7 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.6B USD | 19.5 | 33.8 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 190.3 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
326.9B CNY | 21.5 | 17.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.9B CHF | -40.7 | -119.6 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 36.6 | 25.2 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.3B USD | 107.3 | 47.1 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.9B USD | 9.8 | 19.9 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26B USD | 31.9 | 29.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.1 |
| Median | 0.2 |
| 70th Percentile | 0.4 |
| Max | 901.8 |
Other Multiples
Physiomics PLC
Glance View
Physiomics Plc engages in the provision of outsourced systems and computational biology services to pharmaceutical companies. The company is headquartered in Oxford, Oxfordshire and currently employs 7 full-time employees. The company went IPO on 2004-12-20. The firm offer Virtual Tumour technology and other tools to predict the effects of cancer treatments. The Company’s Virtual Tumour software platform is used to simulate the effects of anti-cancer agents on pre-clinical and human tumors. The company is used by companies ranging from startup biotech to global large-cap pharmaceuticals. The firm provides a range of Pharmacokinetic/Pharmacodynamics (PK/PD) services, usually in support of smaller companies where this function is outsourced. The Company’s services include oncology specialists, mechanistic modelling, PK/PD, quantitative systems pharmacology and mathematical modelling.
